Last checked at 11 Jun 2020 12:00
ImmuPharma PLC
("ImmuPharma" or the "Company")
Director/PDMR Shareholding
ImmuPharma (LSE:IMM) announces that on 11 June 2020, Dr Robert Zimmer, a Director of the Company, transferred 20,000,000 ordinary shares of 10 pence each ("Ordinary Shares") to Luca & Associates AG, an entity connected with Dr Zimmer, and of which he is President and a shareholder.
Following this transaction, Dr Zimmer remains interested in 27,344,514 Ordinary Shares as follows:
Shareholder | Number of Ordinary Shares | % of issued share capital | ||||||||||||||||
Dr R Zimmer | 4,551,553 | 2.49% | ||||||||||||||||
Mrs E Zimmer | 792,961 | 0.43% | ||||||||||||||||
Luca & Associates AG | 22,000,000 | 12.02% | ||||||||||||||||
Total | 27,344,514 | 14.94% | ||||||||||||||||
For further information please contact:
|
| |||||||||||||||||
TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i | ||||||
| ||||||
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: | ImmuPharma PLC | |||||
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) | ||||||
Non-UK issuer |
| |||||
2. Reason for the notification (please mark the appropriate box or boxes with an "X") | ||||||
An acquisition or disposal of voting rights | X | |||||
An acquisition or disposal of financial instruments |
| |||||
An event changing the breakdown of voting rights |
| |||||
Other (please specify)iii: Transfer of shares | X | |||||
3. Details of person subject to the notification obligationiv | ||||||
Name | Luca & Associates AG | |||||
City and country of registered office (if applicable) |
| |||||
4. Full name of shareholder(s) (if different from 3.)v | ||||||
Name |
| |||||
City and country of registered office (if applicable) |
| |||||
5. Date on which the threshold was crossed or reachedvi: | 11 June 2020 | |||||
6. Date on which issuer notified (DD/MM/YYYY): | 11 June 2020 | |||||
7. Total positions of person(s) subject to the notification obligation | ||||||
| % of voting rights attached to shares (total of 8. A) | % of voting rights through financial instruments(total of 8.B 1 + 8.B 2) | Total of both in % (8.A + 8.B) | Total number of voting rights of issuervii | ||
Resulting situation on the date on which threshold was crossed or reached | 12.02% |
| 12.02% | 183,010,920 | ||
Position of previous notification (if applicable) |
|
|
|
| ||
8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii | |||||||||
A: Voting rights attached to shares | |||||||||
Class/type ofshares ISIN code (if possible) | Number of voting rightsix | % of voting rights | |||||||
Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) | Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) | Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) | Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) | ||||||
GB0033711010 | 22,000,000 |
| 12.02% |
| |||||
|
|
|
|
| |||||
|
|
|
|
| |||||
SUBTOTAL 8. A | 22,000,000 | 12.02% | |||||||
| |||||||||
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a)) | |||||||||
Type of financial instrument | Expirationdatex | Exercise/Conversion Periodxi | Number of voting rights that may be acquired if the instrument is exercised/converted. | % of voting rights | |||||
|
|
|
|
| |||||
|
|
|
|
| |||||
|
|
|
|
| |||||
|
| SUBTOTAL 8. B 1 |
|
| |||||
| |||||||||
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b)) | |||||||||
Type of financial instrument | Expirationdatex | Exercise/Conversion Period xi | Physical or cash settlementxii | Number of voting rights | % of voting rights | ||||
|
|
|
|
|
| ||||
|
|
|
|
|
| ||||
|
|
|
|
|
| ||||
|
|
| SUBTOTAL 8.B.2 |
|
| ||||
| |||||||||
9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X") | ||||
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii |
| |||
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary) | X | |||
Namexv | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold | |
DR ZIMMER & OTHERS | 2.92% |
| 2.92% | |
LUCA & ASSOCIATES AG | 12.02% |
| 12.02% | |
|
|
|
| |
|
|
|
| |
TOTAL | 14.94 |
| 14.94 | |
| ||||
10. In case of proxy voting, please identify: | ||||
Name of the proxy holder |
| |||
The number and % of voting rights held |
| |||
The date until which the voting rights will be held |
| |||
| ||||
11. Additional informationxvi | ||||
The notification has arisen as Dr Zimmer has transferred 20,000,000 shares to Luca & Associates AG, an entity connected with Dr Zimmer, and of which he is President and a shareholder.
| ||||
Place of completion | 5, rue du Rhône 68100 Mulhouse France |
Date of completion | 11 June 2020 |
TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i | ||||||
| ||||||
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: | ImmuPharma PLC | |||||
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) | ||||||
Non-UK issuer |
| |||||
2. Reason for the notification (please mark the appropriate box or boxes with an "X") | ||||||
An acquisition or disposal of voting rights | X | |||||
An acquisition or disposal of financial instruments |
| |||||
An event changing the breakdown of voting rights |
| |||||
Other (please specify)iii: Transfer of shares | X | |||||
3. Details of person subject to the notification obligationiv | ||||||
Name | Dr Robert Zimmer | |||||
City and country of registered office (if applicable) |
| |||||
4. Full name of shareholder(s) (if different from 3.)v | ||||||
Name |
| |||||
City and country of registered office (if applicable) |
| |||||
5. Date on which the threshold was crossed or reachedvi: | 11 June 2020 | |||||
6. Date on which issuer notified (DD/MM/YYYY): | 11 June 2020 | |||||
7. Total positions of person(s) subject to the notification obligation | ||||||
| % of voting rights attached to shares (total of 8. A) | % of voting rights through financial instruments(total of 8.B 1 + 8.B 2) | Total of both in % (8.A + 8.B) | Total number of voting rights of issuervii | ||
Resulting situation on the date on which threshold was crossed or reached | 14.94% |
|
| 183,010,920 | ||
Position of previous notification (if applicable) |
|
|
|
| ||
8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii | |||||||||
A: Voting rights attached to shares | |||||||||
Class/type ofshares ISIN code (if possible) | Number of voting rightsix | % of voting rights | |||||||
Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) | Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) | Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) | Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) | ||||||
GB0033711010 | 5,344,514 | 22,000,000 | 2.92% | 12.02% | |||||
|
|
|
|
| |||||
|
|
|
|
| |||||
SUBTOTAL 8. A | 27,344,514 | 14.94% | |||||||
| |||||||||
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a)) | |||||||||
Type of financial instrument | Expirationdatex | Exercise/Conversion Periodxi | Number of voting rights that may be acquired if the instrument is exercised/converted. | % of voting rights | |||||
|
|
|
|
| |||||
|
|
|
|
| |||||
|
|
|
|
| |||||
|
| SUBTOTAL 8. B 1 |
|
| |||||
| |||||||||
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b)) | |||||||||
Type of financial instrument | Expirationdatex | Exercise/Conversion Period xi | Physical or cash settlementxii | Number of voting rights | % of voting rights | ||||
|
|
|
|
|
| ||||
|
|
|
|
|
| ||||
|
|
|
|
|
| ||||
|
|
| SUBTOTAL 8.B.2 |
|
| ||||
| |||||||||
9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X") | ||||
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii | x | |||
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary) |
| |||
Namexv | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold | |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
| ||||
10. In case of proxy voting, please identify: | ||||
Name of the proxy holder |
| |||
The number and % of voting rights held |
| |||
The date until which the voting rights will be held |
| |||
| ||||
11. Additional informationxvi | ||||
The notification has arisen as Dr Robert Zimmer has transferred 20,000,000 ordinary shares to Luca & Associates AG, an entity connected with Dr Robert Zimmer, and of which he is President and a shareholder.
Included in Dr Zimmer's holding are 792,961 shares in the name of his spouse Mrs Elizabeth Zimmer.
| ||||
Place of completion | 5, rue du Rhône 68100 Mulhouse France |
Date of completion | 11 June 2020 |